Because living with PAH brings new challenges, United Therapeutics Corporation and Lung Rx, LLC, the companies that bring you Adcirca™ (tadalafil) tablets, TYVASO® (treprostinil) Inhalation Solution and REMODULIN® (treprostinil sodium) Injection, have created a comprehensive program that can help you learn about PAH and your therapy options while providing emotional support and an opportunity to talk with others who have been down a similar path.
Living PAH brings you an integrative approach to living with PAH. You can participate a little or a lot. You choose the resources you need and the support you want. It’s up to you. Ask your questions and connect to a larger community of doctors, nurses, families and other people living with PAH.
Here’s what you can expect from Living PAH:
- Education, news and support
- Help with insurance, co-pays and more
- The opportunity to talk to others living with PAH
- Personal help when you feel overwhelmed by the challenges of living with PAH or just need someone to talk to who understands the path you’re traveling
Before you begin Living PAH, we would like to know more about you.
Please click the button below to enroll. Thank you.
Please note that Living PAH is only available to patients with PAH who are currently prescribed Adcirca, TYVASO or REMODULIN, their families and loved ones. If you have already enrolled in Living PAH and would like to unsubscribe, click here.
REMODULIN® (treprostinil sodium) Injection
Indications
REMODULIN is indicated for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling
central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the
subcutaneous route, or in whom these risks are considered warranted.
In patients with pulmonary arterial hypertension requiring transition from Flolan® (epoprostenol sodium), REMODULIN is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
Important Safety Information
Chronic intravenous infusions of REMODULIN are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections
(BSI) and sepsis, which may be fatal. REMODULIN should be used only by clinicians experienced in the diagnosis and treatment of PAH. REMODULIN is a potent pulmonary
and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. REMODULIN inhibits platelet
aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. Initiation of REMODULIN must be performed in a setting
with adequate personnel and equipment for physiological monitoring and emergency care. Therapy with REMODULIN may be used for prolonged periods, and the patient’s
ability to administer REMODULIN and care for an infusion system should be carefully considered. Dose should be increased for lack of improvement in, or worsening of,
symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms. Abrupt withdrawal or sudden large reductions in
dosage of REMODULIN may result in worsening of PAH symptoms and should be avoided. Caution should be used in patients with hepatic or renal insufficiency
The most common side effects of REMODULIN included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of REMODULIN. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilation, and edema.
Please see the REMODULIN full Prescribing Information for further details.
REMODULIN is a registered trademark of United Therapeutics Corporation. Flolan is a registered trademark of GlaxoSmithKline.
Adcirca™ (tadalafil) tablets
Indication
Adcirca is a prescription medication used to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
Important Safety Information
You should discuss all of your medical conditions and all medications with your doctor before starting Adcirca.
Do not take Adcirca if you take any medications that contain nitrates (often used for chest pain), as the combination could cause a sudden, unsafe drop in blood pressure. If you experience chest pain after taking Adcirca, contact your doctor.
Adcirca is a type of medication called a PDE5 inhibitor. Adcirca contains the same ingredient (tadalafil) as CIALIS, which is used to treat erectile dysfunction (impotence). If you are taking Adcirca, do not take CIALIS or other PDE5 inhibitors. Also do not take Adcirca if you are allergic to tadalafil or any other ingredient in Adcirca.
PDE5 inhibitors can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your doctor before taking Adcirca, as these conditions may be affected by the action of Adcirca. If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), Adcirca is not recommended for you.
Do not take Adcirca if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both Adcirca and ritonavir (Norvir) at the same time, your dose of Adcirca will need to be adjusted. Taking Adcirca with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (fainting). Inform your doctor if you have kidney or liver problems before taking Adcirca.
In rare cases, men taking PDE5 inhibitors (including tadalafil) for erectile dysfunction reported side effects such as a sudden decrease or loss of vision or hearing, or an erection lasting more than four hours. If you experience any of these side effects, seek medical attention right away.
The most common side effects of Adcirca are headache, muscle pain, nasal swelling, flushing, respiratory tract infection, extremity pain, nausea, back pain, upset stomach and nasal congestion.
Download the full Prescribing Information and Patient Information or call 1-800-545-5979.
TYVASO® (treprostinil) Inhalation Solution
Indication
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs. Tyvaso can increase walk distance in people who also take bosentan (an endothelin receptor antagonist (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). The effects decrease over 4 hours; treatment timing can be adjusted for planned activities.
Important Safety Information
- TYVASO is breathed in (inhaled) through your mouth into your lungs. TYVASO should only be used with the TYVASO Inhalation System.
- The effects of Tyvaso are unknown in patients with lung disease (such as asthma or chronic obstructive pulmonary disease), and in patients under 18 years of age.
- If you have low blood pressure, TYVASO may cause hypotension.
- Because TYVASO reduces the ability of your blood to clot (coagulate), it may increase your risk for bleeding if you are taking blood thinners (anticoagulants) such as warfarin or heparin.
- The use of TYVASO with diuretics (water pills), antihypertensives (medications for heart disease), or other vasodilators (medications that lower blood pressure) may increase your risk of hypotension
Other medical conditions and medicines may effect your use of TYVASO by increasing the risk of side effects or decreasing effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking including:
- If you are taking gemfibrozil (for high cholesterol) or rifampin (for infection) your Tyvaso dosage may need adjustment.
- If you have liver or kidney problems, your ability to tolerate Tyvaso may be affected.
- If you are pregnant, breast-feeding or planning to become pregnant, talk with your healthcare provider about whether you should take Tyvaso.
The most common side effects of TYVASO are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness.
These are not all the possible side effects of TYVASO. Tell your doctor about any side effects that bother you or do not go away. Your doctor may be able to help you manage the side effects.
For more information, please see the Full Prescribing Information, Patient Package Insert and the Tyvaso Inhalation System Instructions for Use manual. These items are available at http://www.Tyvaso.com.
© 2009 United Therapeutics Corporation. All rights reserved.
LPAH_Website_OCT09v.3
